|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Survival of patients with pancreatic cancer II-IV stages depending on the stage, regimen used in the first lineстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 20 июня 2024 г.
- Авторы: Novoselova Kristina A., Vladimirova Liubov Yu, Abramova Natalya A., Storozhakova Anna E., Popova Irina L., Tikhanovskaya Natalya Mikhailovna, Ryadinskaya Ludmila A., Lyanova Aza A., Snezhko Tatyana A., Kabanov Sergey N., Zhuzhelenko Irina A., Kalabanova Elena Aleksandrovna, Svetickaja Jana V., Kornilova Irina, Samaneva Nataliya, Sergeeva Marina M., Salamov Georgy
- Журнал: Journal of Clinical Oncology
- Том: 36
- Номер: 15_suppl
- Год издания: 2018
- Издательство: American Society of Clinical Oncology
- Местоположение издательства: United States
- Первая страница: e16211
- Последняя страница: e16211
- DOI: 10.1200/jco.2018.36.15_suppl.e16211
- Аннотация: Background: The purpose of the study was to analyze the survival of patients with pancreatic cancer II-IV stages depending on the regimen used in the first line. Methods: The data of adults treated in 2013-2017 were studied. OS was calculated using the Kaplan Meier method and the log-rank test. Results: 133 pts were recruited: stage IIA – 26 (19.6%), IIB – 32 (24.1%), III – 29 (21.8%), IV – 46 (34.6%). The median survival was 7 mon (95% CI 1-11.8). The 36-month cumulative survival rate (CSR) was 0.2, and the 60-mon CSR – 0. Probability of surviving past 22 mon was 0.22, the standard error 0.09; past 12 mon – 0.45, the standard error 0.08. OS was associated with surgical treatment: 20-mon CSR with surgery – 0.25, without surgery – 0.4; 36-mon CSR – 0.25 and 0, respectively (p = 0.017). The median survival – 7 mon (95% CI 6.4-12.4) and 6 mon (95% CI 6.5-13.7), respectively. The median survival in st IIA was 6 mon (95% CI 4.2-12.3), IIB – 8 mon (95% CI 5.5-18.9), III – 6.5 mon (95% CI 4.1-14.8), IV - 6 mon (95% CI 4.7-13.7). 20-mon CSR in st IIA was 0.75, IIB – 0.4, III – 0.43, IV – 0.15 (p = 0.05). OS depended on the first-line therapy: 20-mon CSR in GEM/GEMCAP – 0.35 (median survival 6.5 mon, 95% CI 6.3-11.1), GEMOX – 0.28 (median survival 9 mon, 95% CI 6.2-16.8), FOLFOX/OXCAP/Capecitabin – 0.18 (median survival 3.5 mon, 95% CI 9.9-33.6), FOLFIRI/FOLFIRINOX – 0.36 (median survival 8 mon, 85% CI 8.5-33.2) (p = 0.01). Conclusions: The highest OS was registered in undergone surgery pts, pts with IIA stage of the disease and in pts with GEM/GEMCAP or FOLFIRI/FOLFIRINOX as the first-line therapy.
- Добавил в систему: Владимирова Любовь Юрьевна